Blog
RSS FeedPosted by Michael Wonder on 16 Dec 2023
Has the Centers for Medicare Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations?
15 December 2023 - The US Inflation Reduction Act of 2022 created several major policy changes to the pricing of prescription ...
Posted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...
Posted by Michael Wonder on 11 Sep 2023
An alternative measure of health for value assessment: the equal value life-year
10 September 2023 - The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the ...
Posted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 18 Apr 2023
Added therapeutic benefit of top selling brand name drugs in Medicare
18 April 2023 - What was the added therapeutic benefit of the 50 top selling drugs in Medicare in 2020, ...
Posted by Michael Wonder on 18 Apr 2023
Cost effectiveness thresholds used by study authors (1990-2021)
18 April 2023 - For decades, many US authors of cost effectiveness analyses referenced a common benchmark or threshold—$50 000 per quality-adjusted ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 01 Nov 2022
Association between US drug price and measures of efficacy for oncology drugs approved by the US FDA from 2015 to 2020
31 October 2022 - The past five years have seen a marked increase in the number of cancer therapies on the ...
Posted by Michael Wonder on 20 Oct 2022
Drugs should be priced based on one factor – value
20 October 2022 - For a number of years, the price of drugs has drawn extraordinary attention. ...
Posted by Michael Wonder on 26 May 2022
From scientific discovery to covered treatments: understanding the payer perspective as a keystone to achieving high value care
26 May 2022 - The mission of the National Institutes of Health is to translate scientific discovery into health by designing ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 09 Dec 2021
Consensus lacking on ‘value’ for new anti-cancer drugs
8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, ...
Posted by Michael Wonder on 14 Nov 2021
Drug pricing debate redux — should cost effectiveness analysis be used now to price pharmaceuticals?
13 November 2021 - The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for ...
Posted by Michael Wonder on 11 Oct 2021
Paying for cancer drugs that prove their benefit
11 October 2021 - The United States pays prices for brand name drugs that are estimated to be 256% higher than ...
Posted by Michael Wonder on 09 Sep 2021
Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review
8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...